Skip to main content
SpringerLink
Log in

Spezifische Immuntherapie/Hyposensibilisierung

  • Chapter
Fortschritte der praktischen Dermatologie und Venerologie

Part of the book series: Fortschritte der praktischen Dermatologie und Venerologie ((DERMATOLOGIE,volume 21))

Auszug

Allergenmeidung, symptomatische Pharmakotherapie und Hyposensibilisierung (spezifische Immuntherapie [SIT]) sind die grundlegenden Maßnahmen im Management allergologischer Erkrankungen. Die Korrektur der aberranten Immunregulation durch kontrollierte Applikation ansteigender Allergendosen bei der Hyposensibilisierung besitzt dabei die größte Attraktivität. IgE-vermittelte Atemwegserkrankungen durch bestimmte Allergene und die ebenfalls IgE-vermittelte Hymenopterengiftallergie können heute damit sehr wirksam und, bei Beachtung von Indikationen und Kontraindikationen, auch sicher therapiert werden. Grundlage hierfür sind aussagestarke klinische Studien, die Verfügbarkeit von Allergenzubereitungen hoher Qualität sowie ein breiter Konsensus zu den Modalitäten der Anwendung dieser Therapieform. In den letzten Jahren wurde in Ergänzung zur subkutanen Immuntherapie ein neuer Applikationsweg der Allergene, die sublinguale Immuntherapie (SLIT), erschlossen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA (2004) Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells. J Exp Med 199: 1567–1575

    Article  PubMed  CAS  Google Scholar 

  2. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J (1997) Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 27: 1131–1139

    Article  PubMed  CAS  Google Scholar 

  3. Daeron M, Malbec O, Latour S, Arock M, Fridman WH (1995) Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 95: 577–585

    Article  PubMed  CAS  Google Scholar 

  4. Durham SR, Till SJ (1998) Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 102: 157–164

    Article  PubMed  CAS  Google Scholar 

  5. Hawrylowicz CM, O’Garra A (2005) Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 5: 271–283

    Article  PubMed  CAS  Google Scholar 

  6. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA (2003) IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33: 1205–1214

    Article  PubMed  CAS  Google Scholar 

  7. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR (1995) Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 154: 4187–4194

    PubMed  CAS  Google Scholar 

  8. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR (2004) Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172: 3252–3259

    PubMed  CAS  Google Scholar 

  9. Oettgen HC, Geha RS (2001) IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 107: 429–440

    Article  PubMed  CAS  Google Scholar 

  10. Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J (1999) Decreased release of histamine and sulfido-leukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of interleukin-10 and interferon-gamma production of T cells. J Allergy Clin Immunol 103: 326–332

    Article  PubMed  CAS  Google Scholar 

  11. Saltoum CA (2002) Update on efficacy of allergen immunotherapy for allergic rhinitis and asthma. Allergy Asthma Proc 23: 377–380

    Google Scholar 

  12. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT (1993) Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 178: 2123–2130

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Brockow K, Kiehn M, Riethmüller C, Vieluf D, Berger J, Ring J (1997) Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immuno 100:458–63

    Article  CAS  Google Scholar 

  2. Kontou-Fili K (2008) High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63:376–378

    Article  PubMed  CAS  Google Scholar 

  3. Ruëff F, Przybilla B (2008) Insektengifthyposensibilisierung-Nebenwirkungen und Therapieerfolg. Hautarzt 59: 200–205

    Article  PubMed  Google Scholar 

  4. Ruëff F, Wenderoth A, Przybilla B (2001) Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108: 1027–32

    Article  PubMed  Google Scholar 

Literatur

  1. Biló BM, Ruëff F, Mosbech H, Bonifazi F, Oude-Elberink JN (2005) Diagnosis of Hymenoptera venom allergy. Allergy 60: 1339–49

    Article  PubMed  Google Scholar 

  2. Bonifazi F, Jutel M, Biló BM, Birnhaum J, Müller U (2005) Prevention and treatment of Hymenoptera venom allergy: guidelines for clinical practice. Allergy 60: 1459–70

    Article  PubMed  CAS  Google Scholar 

  3. Kleine-Tebbe J, Bergmann KC, Friedrichs F, Fuchs T, Jung K, Klimek L, Kühr J, Lässig W, Lepp U, Niggemann B, Rakoski J, Rebien W, Renz H, Saloga J, Simon J, Sitter H, Virchow C, Worm M (2006) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA) und der Gesellschaft für pädiatrische Allergologie und Umweltmedizin (GPA). Allergo J 15: 56–74

    Google Scholar 

  4. Müller U, Helbling A, Berchtold E (1992) Immunotherapy with honey bee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 89: 529–535

    Article  PubMed  Google Scholar 

  5. Müller U, Mosbech H (eds) (1993) Immunotherapy with Hymenoptera venoms. Position paper. Allergy 48 (Suppl 14): 37–46

    Google Scholar 

  6. Przybilla B, Müller U, Jarisch R, Ruëff F (2004) Erhöhte basale Serumtryptasekonzentration oder Mastozytose als Risikofaktor der Hymenopterengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI). Allergo J 13: 440–2

    Google Scholar 

  7. Przybilla B, Ruëff F, Fuchs T, Pfeiffer C, Rakoski J, Stolz W, Vieluf D (2004) Insektengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI). Allergo J 13: 186–190

    Google Scholar 

  8. Ruëff F, Przybilla B, Müller U, Mosbech H (1996) The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Allergy 51: 216–225

    PubMed  Google Scholar 

  9. Ruëff F, Wenderoth A, Przybilla B (2001) Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 108: 1027–32

    Article  PubMed  Google Scholar 

  10. Valentine MD, Schuberth KC, Kagey-Sobotka A, Graft DF, Kwiterovich KA, Szklo M, Lichtenstein LM (1990) The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 323: 1601–1603

    PubMed  CAS  Google Scholar 

Literatur

  1. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, Creticos PJ, Dayer JM, Durham SR, Demoly P, Goldstein RJ, Ishikawa T, Ito K, Kraft D, Lambert PH, Løwenstein H, Müller U, Norman PS, Reisman RE, Valenta R, Valovirta H, Yssel H (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. Ann Allergy Asthma Immunol 81:401–405

    Article  PubMed  CAS  Google Scholar 

  2. Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW, Bieber T, Thomas WR, Valenta R, Zuberbier T, Sager A, Novak N (2007) Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutatneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 37:1277–1285

    Article  PubMed  CAS  Google Scholar 

  3. Darsow U, Ring J, Kapp A, Werfel T (2008) Spezifische Immuntherapie bei atopischem Ekzem. Allergo J 17: 233–236

    Google Scholar 

  4. Kleine-Tebbe J, Bergmann KC, Friedrichs F, Fuchs T, Jung K, Klimek L, Kühr J, Lässig W, Lepp U, Niggemann B, Rakoski J, Rebien W, Renz H, Saloga J, Simon J, Sitter H, Virchow C, Worm M (2006) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA) und der Gesellschaft für pädiatrische Allergologie und Umweltmedizin (GPA). Allergo J 15: 56–74

    Google Scholar 

  5. Leynadier F, Herman D, Vervloet D, Andre C (2000) Specific immunotherapy with a standardized latex extraxt versus placebo in allergic healthcare workers. J Allergy Clin Immunol 106:585–590

    Article  PubMed  CAS  Google Scholar 

  6. Marks JG Jr, Trautlein JJ, Epstein WL, Laws DM, Sicard GR (1987) Oral hyposensitization to poison ivy and poison oak. Arch Dermatol 123:476–478

    Article  PubMed  Google Scholar 

  7. Morris DL (1998) Intradermal testing and sublingual desensitization for nickel. Cutis 61: 129–32

    PubMed  CAS  Google Scholar 

  8. Müller UR, Haeberli G (2005) Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 115:606–610

    Article  PubMed  CAS  Google Scholar 

  9. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leungs DYM (1992) Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90:256–262

    Article  PubMed  CAS  Google Scholar 

  10. Panzani RC, Schiavino D, Nucera E, Pellegrino S, Fais G, Schinco G, Patriarca G (1995) Oral hyposensitization to nickel allergy: preliminary clinical results. Int Arch Allergy Immunol 107:251–254

    Article  PubMed  CAS  Google Scholar 

  11. Reginella RF, Fairfield JC, Marks JG Jr (1989) Hyposensitization to poison ivy after working in a cashew nut shell oil processing factory. Contact Dermatitis 20:274–279

    Article  PubMed  CAS  Google Scholar 

  12. Schiavino D, Nucera E, Alonzi C, Buonomo A, Pollastrini E, Roncallo C, De Pasquale T, Lombardo C, La Torre G, Sabato V, Pecora V, Patriarca G (2006) A clinical trial of oral hyposensitization in systemic allergy to nickel. Int J Immunopathol Pharmacol 19:593–600

    PubMed  CAS  Google Scholar 

  13. Werfel T, Breuer K, Ruëff F, Przybilla B, Worm M, Grewe M, Ruzicka T, Brehler R, Wolf H, Schnitker J, Kapp A (2006) Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61: 202–205

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Frauenlobstraße 9-11, 80337, München

    Ricarda Eben Dr. med., Franziska Ruëff Priv.-Doz. Dr. med. & Bernhard Przybilla Prof. Dr. med.

  2. Universität Mainz KöR, Universitäts-Hautklinik, Universitätsmedizin der Johannes Gutenberg, Langenbeckstraße 1, 55131, Mainz

    Iris Bellinghausen Dr. rer. nat. & Joachim Saloga Prof. Dr. med.

  3. Klinik und Poliklinik für Dermatologie und Allergologie, Technische Universität München, Biedersteiner Straße 29, 80802, München

    Knut Brockow Priv.-Doz. Dr. med.

  4. Abteilung Dermatologie und Venerologie, Georg-August-Universität Göttingen, Von-Siebold-Straße 3, 37075, Gottingen

    Thomas Fuchs Prof. Dr. med.

Authors
  1. Ricarda Eben Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iris Bellinghausen Dr. rer. nat.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Knut Brockow Priv.-Doz. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Fuchs Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Franziska Ruëff Priv.-Doz. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joachim Saloga Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bernhard Przybilla Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Thomas Ruzicka Prof. Dr. med. Dr. h.c. Hans Wolff Prof. Dr. med. Peter Thomas Prof. Dr. med. Jörg Prinz Prof. Dr. med.

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Eben, R. et al. (2009). Spezifische Immuntherapie/Hyposensibilisierung. In: Ruzicka, T., Wolff, H., Thomas, P., Prinz, J. (eds) Fortschritte der praktischen Dermatologie und Venerologie. Fortschritte der praktischen Dermatologie und Venerologie, vol 21. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-77148-7_87

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-77148-7_87

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-77121-0

  • Online ISBN: 978-3-540-77148-7

Publish with us

Policies and ethics

Search

Navigation